

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	1919
Policy Title	Serum eye drops for the treatment of severe ocular surface disease (All ages)
Clinical Reference Group	Specialised Ear & Ophthalmology
Which stakeholders were contacted to be involved in policy development?	CRG stakeholders list, and all CRG members.
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	The Royal College of Ophthalmology provided stakeholder feedback. They were supportive of the policy proposition, though had queries regarding the inclusion and stopping criteria. The policy has been updated to clarify the inclusion criteria and withdrawal strategies in line with their comments.
Which stakeholders have actually been involved?	Royal College of Ophthalmology, Royal National Institute for Blind People, Calderdale and Huddersfield NHS Foundation Trust, Leeds Teaching Hospital, Mid-Cheshire NHS Foundation Trust and three individuals not responding on behalf of organisations.
Explain reason if there is any difference from previous question	
Identify any particular stakeholder organisations that may be key to the	None

<p>policy development that you have approached that have yet to be engaged. Indicate why?</p>	
<p>How have stakeholders been involved? What engagement methods have been used?</p>	<p>Stakeholders have been involved in the policy working group. The draft policy proposition was distributed to stakeholders via email for a period of 2 weeks of stakeholder testing between 7th and 22nd January 2020.</p> <p>Stakeholders were asked to submit their responses via email, using a standard response and in line with NHS England's standard processes for developing clinical commissioning policies. There were 10 respondents.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Eligibility criteria clarified to highlight acute indications, including graft-versus-host disease</p> <p>Stopping criteria modified to clarify that withdrawal period can be curtailed when symptoms rapidly return.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>Policy will be published following approval by NHS England.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>No further public consultation required as per process for policy statement.</p>